There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paratek Pharmaceuticals (PRTK) and Nektar Therapeutics (NKTR) with bullish sentiments.
Paratek Pharmaceuticals (PRTK)
Ladenburg analyst Michael Higgins maintained a Buy rating on Paratek Pharmaceuticals today and set a price target of $18. The company’s shares closed yesterday at $5.11, close to its 52-week low of $4.50.
According to TipRanks.com, Higgins ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.9% and a 31.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Zynerba Pharmaceuticals, and Ovid Therapeutics Inc.
Currently, the analyst consensus on Paratek Pharmaceuticals is a Strong Buy with an average price target of $21.25.
See today’s analyst top recommended stocks >>
Nektar Therapeutics (NKTR)
In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Nektar Therapeutics, with a price target of $82. The company’s shares closed yesterday at $32.98, close to its 52-week low of $29.22.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.7% and a 42.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Nektar Therapeutics is a Strong Buy with an average price target of $81, a 145.6% upside from current levels. In a report released today, Mizuho Securities also assigned a Buy rating to the stock with a $81 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.